ArticleJournal of pain research2026
Electroacupuncture Combined with Diclofenac Emulgel for Post-Traumatic Ankle Osteoarthritis: A Randomized Controlled Trial Protocol.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Post-traumatic ankle osteoarthritis (PTAOA) is a common chronic condition associated with persistent pain, functional limitation, and reduced quality of life. Electroacupuncture (EA) has shown potential as a non-pharmacological intervention for osteoarthritis, but high-quality evidence in PTAOA remains limited. This study aims to evaluate the efficacy and safety of EA combined with topical diclofenac emulgel in patients with PTAOA and to explore potential inflammatory mechanisms. Patients and Methods: This is a single-center, randomized, sham-controlled superiority trial. A total of 78 patients with PTAOA will be randomly assigned in a 1:1 ratio to either the EA group or the sham acupuncture (SA) group. Both groups will receive topical diclofenac emulgel (2 g per dose, twice daily) for 4 weeks, together with standardized education regarding PTAOA management. Participants in the EA and SA groups will receive 20 treatment sessions over 4 weeks. The primary outcome is the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS). Secondary outcomes include the Short-Form McGill Pain Questionnaire (SF-MPQ), Foot and Ankle Ability Measure (FAAM), 36-Item Short Form Health Survey (SF-36), musculoskeletal ultrasound findings, and serum levels of TNF-α, IL-6, and IL-1β. Clinical outcomes will be assessed at baseline, week 2, week 4, and week 8, while musculoskeletal ultrasound and serum inflammatory markers will be assessed at baseline and week 4. Discussion: This study will provide more comprehensive evidence regarding the efficacy and safety of EA combined with topical diclofenac emulgel for PTAOA and may help clarify its potential anti-inflammatory effects.Trial registration Registry: International Traditional Medicine Clinical Trial Registry (ITMCTR), No. ITMCTR2025001585; registered on 24 July 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.